A Double-Blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer.

Trial Profile

A Double-Blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs Fulvestrant (Primary) ; Tamoxifen
  • Indications Advanced breast cancer; Menopause
  • Focus Registrational; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Jan 2016 Results of a biomarker study in patients from this trial (n=2) and another pahse III trial (n=30) published in the International Journal of Cancer.
    • 04 Jun 2012 Actual end date changed from 1 Jun 2007 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top